Protocol Summary

Protocol No.: OCR37042

Sponsor Protocol No.: IRB20202065; NANOPAC-2020-01

Protocol Title.: Trial of NanoPac Intratumoral Injection in Lung Cancer

Principal Investigator: Mehta, Hiren

Objective: This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.

Description: NanoPac is very small (submicron) particles of the chemotherapy drug, paclitaxel, which is administered intravenously in a number of types of cancer. These submicron particles are injected directly into solid tumors to target cancer at the site of disease with less systemic exposure than intravenously administered chemotherapy. In this study, the submicron particle paclitaxel will be injected directly into tumors in the lungs of people with small cell or non-small cell lung cancer. All subjects in this study will receive NanoPac and will be evaluated to see if NanoPac is safe and has an effect on the tumor within the lung.

Phase: Phase II

Age Group: Adult

Age: 18 Years - N/A

Gender: All

Scope: National

Treatment:

Experimental: NanoPac
Intratumoral injection of NanoPac 15 mg/mL at a volume of up to 20% of the total calculated tumor and lymph node volume (not to exceed 40 mL) on up to three occasions 4 weeks apart.

Detailed Eligibility:

Inclusion Criteria: - Signed informed consent; - Age ≥18 years and able to tolerate the EBUS-TBNI procedure; - Histologically/cytologically confirmed lung cancer. Eligible subjects may include, for example: primary or recurrent non-resectable disease, locally advanced stages II and III with nodal disease, stage IV advanced disease; - At least one lesion documented via imaging (within 4 weeks of Screening) which can be accessed using EBUS-TBNI; - Subject is not a candidate for surgery; - Has received SOC chemotherapy; adequate hematologic recovery must be confirmed according to the institution's SOC; - Performance Status (ECOG) 0-2 at study entry; - Life expectancy of at least 6 months; - Adequate marrow, liver, and renal function at study entry; - ANC ≥ 1.5 x 109/L; - Hemoglobin ≥ 9.0 grams/dL; - Platelets ≥ 75 x 109/L; - Total bilirubin ≤ 1.5x institutional ULN; - AST/ ALT ≤ 2.5x institutional ULN; - Creatinine ≤ 1.5x institutional ULN; - Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child-bearing potential.* Exclusion Criteria: - Malignant Airway Obstruction; - Known hypersensitivity to study agent; - Pregnant or breastfeeding women.

Applicable Conditions:

  • Lung Cancer
  • Participation Institution:

  • UF Gainesville : Christina Eagan
  • Contact:
    Christina Eagan
    Email: christina.eagan@medicine.ufl.edu

    More Information: View study listing on ClinicialTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT04314895